Context Therapeutics initiated with a Buy at Guggenheim

Guggenheim initiated coverage of Context Therapeutics (CNTX) with a Buy rating and $5 price target The firm’s investment thesis on the stock is centered on the company’s differentiated approach to addressing “clinically validated but challenging” targets on solid tumors, which collectively represent a significant $30B U.S. total addressable market in aggregate across focus tumor type, the analyst tells investors in a research note. With shares trading at zero enterprise value, there is “asymmetric risk/reward” for Context Therapeutics, Guggenheim added.